Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMIT-Dapa: Intensive Metabolic Intervention with Forxiga in Early T2DM
NCT02561130Phase 4Completed
- Sponsor
- Population Health Research Institute
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Population Health Research Institute. Primary endpoint: Number of Participants Achieving Drug-free Diabetes Remission at 24 weeks. Started Dec 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02561130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561130.